DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Information source: Teva Pharmaceutical Industries
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Persistent Asthma

Intervention: Fluticasone propionate Multidose Dry Powder Inhaler (Fp MDPI) (Drug); Fluticasone propionate /salmeterol MDPI (FS MDPI) (Drug); Fluticasone propionate HFA Inhalation Aerosol (Drug); Fluticasone propionate/salmeterol dry powder formulation (Drug)

Phase: Phase 3

Status: Active, not recruiting

Sponsored by: Teva Branded Pharmaceutical Products, R&D Inc.

Official(s) and/or principal investigator(s):
Teva Medical Expert, MD, Study Director, Affiliation: TEVA

Summary

The primary objective of the study is to evaluate the long-term safety of fluticasone propionate inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation powder in 2 strengths when administered with the Teva MDPI device over 26 weeks in patients with persistent asthma

Clinical Details

Official title: A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Incidence of adverse events

Secondary outcome:

Oropharyngeal examination for oral candidiasis

Clinical laboratory evaluations

Vital signs

12-lead ECG findings

Physical examination

Change in medical history

Concomitant medication usage throughout the study

Change in 24-hour urinary cortisol levels

Eligibility

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Best pre-bronchodilator FEV1 of greater than 40% of their predicted normal value. 2. Patients must have a treatment regimen that includes a short-acting β2 agonist (SABA) (albuterol) for use as needed and either an inhaled corticosteroid (ICS) or an ICS/long-acting β2 agonist (LABA) as a preventative treatment for a minimum of 8 weeks before the SV. Patients currently taking low-dose ICS without LABA are not eligible for this study. Patients currently taking low-dose ICS/LABA may only be entered into the mid ICS strength. All patients must have been maintained on a stable dose of ICS or ICS/LABA for 4 weeks prior to the SV (or pre-SV if necessary) at 1 qualifying doses 3. To meet reversibility of disease criteria, the patient must demonstrate a ≥12% reversibility of FEV1 (and 200 mL for patients aged18 years and older) within 30 minutes following 4 inhalations of albuterol at the SV. Historic reversibility within the past 12 months of the SV may be used to meet this criterion. 4. Written informed consent/assent is obtained. For adult patients (aged 18 years and older, or as applicable per local regulations), the written informed consent form (ICF) must be signed and dated by the patient before conducting any study-related procedure. For minor patients (aged 12 to 17 years, or as applicable per local regulations), the written ICF must be signed and dated by the parent/legal guardian and the written assent form must be signed and dated by the patient (if applicable) before conducting any study-related procedure. Note: Age requirements are as specified by local regulations. 5. Outpatient >= 12 years of age on the date of consent/assent. . 6. Asthma diagnosis: The patient has a diagnosis of asthma as defined by the National Institutes of Health (NIH). The asthma diagnosis has been present for a minimum of 3 months and has been stable (defined as no exacerbations and no changes in medication) for at least 30 days before providing informed consent. 7. The patient is able to perform acceptable and repeatable spirometry. 8. The patient is able to perform peak expiratory flow (PEF) with a handheld peak flow meter. 9. The patient is able to use a metered-dose inhaler (MDI) device without a spacer device and a MDPI device. 10. The patient is able to withhold (as judged by the investigator) his or her regimen of ICS or study drug, and rescue medication for at least 6 hours before the SV and before all treatment visits where spirometry is performed. 11. The patient/parent/legal guardian/caregiver is capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements. 12. SABAs: All patients must be able to replace their current SABA with albuterol/salbutamol HFA inhalation aerosol at the SV for use as needed for the duration of the study. 13. Female patients may not be pregnant, breastfeeding, or attempting to become pregnant.

- -Other criteria may apply, please contact the investigator for more information

Exclusion Criteria: 1. The patient has a history of a life-threatening asthma exacerbation that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures. 2. The patient is pregnant or lactating, or plans to become pregnant during the study period or for 30 days after the study . 3. The patient has participated as a randomized patient in any investigational drug study within the 30 days preceding the SV (or prescreening visit, as applicable) or plans to participate in another investigational drug study at any time during this study. 4. The patient has previously participated in an Fp MDPI or FS MDPI study. 5. The patient has a known hypersensitivity to any corticosteroid, salmeterol, or any of the excipients in the study drug or rescue medication formulation (ie, lactose). 6. The patient has been treated with any known strong cytochrome P450 (CYP) 3A4 inhibitors (eg, azole antifungals, ritonavir, or clarithromycin) within 30 days before the SV or plans to be treated with any strong CYP3A4 inhibitor during the study. 7. The patient has been treated with any of the prohibited medications during the prescribed (per protocol) washout periods before the SV. 8. The patient currently smokes or has a smoking history of 10 pack-years or more (a pack-year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient may not have used tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco). 9. The patient has a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that has not resolved at least 2 weeks before the SV. 10. The patient has a history of alcohol or drug abuse within 2 years preceding the SV. 11. The patient has had an asthma exacerbation requiring systemic corticosteroids within 30 days before the SV, or has had any hospitalization for asthma within 2 months before the SV. 12. Initiation or dose escalation of immunotherapy (administered by any route) is planned during the study period. However, patients who initiated immunotherapy 90 days or more before the SV and have been on a stable (maintenance) dose for 30 days or more before the SV may be considered for inclusion. 13. The patient has used immunosuppressive medications within 4 weeks before the SV. 14. The patient is unable to tolerate or unwilling to comply with the appropriate washout periods and withholding of all applicable medications. (Patients that require continuous treatment with β-blockers, monoamine oxidase inhibitors, tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids are excluded). 15. The patient has untreated oral candidiasis at the SV. Patients with clinical visual evidence of oral candidiasis who agree to receive treatment and comply with appropriate medical monitoring may enter the study. 16. The patient has a history of a positive test for human immunodeficiency virus, active hepatitis B virus, or hepatitis C infection. 17. The patient is either an employee or an immediate relative of an employee of the clinical investigational center. 18. A member of the patient's household is participating in the study at the same time. However, after the enrolled patient completes or discontinues participation in the study, another patient from the same household may be screened. 19. The patient has a disease/condition that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.

- Other criteria may apply, please contact the investigator for more information

Locations and Contacts

Teva Investigational Site 12068, Birmingham, Alabama, United States

Teva Investigational Site 12112, Mobile, Alabama, United States

Teva Investigational Site 12130, Pell City, Alabama, United States

Teva Investigational Site 12119, Little Rock, Alaska, United States

Teva Investigational Site 12076, Phoenix, Arizona, United States

Teva Investigational Site 12135, Scottsdale, Arizona, United States

Teva Investigational Site 12132, Tucson, Arizona, United States

Teva Investigational Site 12102, Fountain Valley, California, United States

Teva Investigational Site 12104, Fresno, California, United States

Teva Investigational Site 12123, Fullerton, California, United States

Teva Investigational Site 12103, Huntington Beach, California, United States

Teva Investigational Site 12073, Long Beach, California, United States

Teva Investigational Site 12077, Mission Viejo, California, United States

Teva Investigational Site 12098, Napa, California, United States

Teva Investigational Site 12149, Northridge, California, United States

Teva Investigational Site 12081, Orange, California, United States

Teva Investigational Site 12100, Rancho Mirage, California, United States

Teva Investigational Site 12133, Riverside, California, United States

Teva Investigational Site 12146, Riverside, California, United States

Teva Investigational Site 12075, Rolling Hills Estates, California, United States

Teva Investigational Site 12074, San Diego, California, United States

Teva Investigational Site 12150, San Diego, California, United States

Teva Investigational Site 12064, San Jose, California, United States

Teva Investigational Site 12061, Stockton, California, United States

Teva Investigational Site 12141, Walnut Creek, California, United States

Teva Investigational Site 12043, Denver, Colorado, United States

Teva Investigational Site 12051, Denver, Colorado, United States

Teva Investigational Site 12091, Waterbury, Connecticut, United States

Teva Investigational Site 12078, Fort Lauderdale, Florida, United States

Teva Investigational Site 12140, Hialeah, Florida, United States

Teva Investigational Site 12066, Kissimee, Florida, United States

Teva Investigational Site 12120, Miami, Florida, United States

Teva Investigational Site 12127, Miami, Florida, United States

Teva Investigational Site 12148, Miami, Florida, United States

Teva Investigational Site 12114, Ocala, Florida, United States

Teva Investigational Site 12055, Sarasota, Florida, United States

Teva Investigational Site 12048, Tallahassee, Florida, United States

Teva Investigational Site 12122, Tamarac, Florida, United States

Teva Investigational Site 12086, Winter Park, Florida, United States

Teva Investigational Site 12111, Gainesville, Georgia, United States

Teva Investigational Site 12070, Lawrenceville, Georgia, United States

Teva Investigational Site 12072, Marietta, Georgia, United States

Teva Investigational Site 12106, Coeur d'Alene, Idaho, United States

Teva Investigational Site 12117, Eagle, Idaho, United States

Teva Investigational Site 12065, River Forest, Illinois, United States

Teva Investigational Site 12059, Shiloh, Illinois, United States

Teva Investigational Site 12056, Overland Park, Kansas, United States

Teva Investigational Site 12138, Fort Mitchell, Kentucky, United States

Teva Investigational Site 12092, Owensboro, Kentucky, United States

Teva Investigational Site 12087, Covington, Louisiana, United States

Teva Investigational Site 12095, Bangor, Maine, United States

Teva Investigational Site 12042, Baltimore, Maryland, United States

Teva Investigational Site 12124, Baltimore, Maryland, United States

Teva Investigational Site 12052, North Dartmouth, Massachusetts, United States

Teva Investigational Site 12139, Minneapolis, Minnesota, United States

Teva Investigational Site 12137, Plymouth, Minnesota, United States

Teva Investigational Site 12079, Columbia, Missouri, United States

Teva Investigational Site 12067, Rolla, Missouri, United States

Teva Investigational Site 12060, Saint Louis, Missouri, United States

Teva Investigational Site 12108, St Louis, Missouri, United States

Teva Investigational Site 12057, St. Louis, Missouri, United States

Teva Investigational Site 12128, Warrensberg, Missouri, United States

Teva Investigational Site 12136, Bellevue, Nebraska, United States

Teva Investigational Site 12115, Las Vegas, Nevada, United States

Teva Investigational Site 12131, Las Vegas, Nevada, United States

Teva Investigational Site 12126, Ocean, New Jersey, United States

Teva Investigational Site 12129, Verona, New Jersey, United States

Teva Investigational Site 12058, Rochester, New York, United States

Teva Investigational Site 12113, Rockville Centre, New York, United States

Teva Investigational Site 12047, Charlotte, North Carolina, United States

Teva Investigational Site 12085, Charlotte, North Carolina, United States

Teva Investigational Site 12144, Winston-Salem, North Carolina, United States

Teva Investigational Site 12053, Canton, Ohio, United States

Teva Investigational Site 12094, Cincinnati, Ohio, United States

Teva Investigational Site 12105, Cincinnati, Ohio, United States

Teva Investigational Site 12107, Sylvania, Ohio, United States

Teva Investigational Site 12069, Tiffin, Ohio, United States

Teva Investigational Site 12045, Oklahoma City, Oklahoma, United States

Teva Investigational Site 12080, Oklahoma City, Oklahoma, United States

Teva Investigational Site 12083, Oklahoma City, Oklahoma, United States

Teva Investigational Site 12062, Eugene, Oregon, United States

Teva Investigational Site 12097, Medford, Oregon, United States

Teva Investigational Site 12049, Portland, Oregon, United States

Teva Investigational Site 12134, Bryn Mawr, Pennsylvania, United States

Teva Investigational Site 12090, Philadelphia, Pennsylvania, United States

Teva Investigational Site 12089, Providence, Rhode Island, United States

Teva Investigational Site 12088, Warwick, Rhode Island, United States

Teva Investigational Site 12096, Charleston, South Carolina, United States

Teva Investigational Site 12147, Spartanburg, South Carolina, United States

Teva Investigational Site 12121, Dallas, Texas, United States

Teva Investigational Site 12110, Duncanville, Texas, United States

Teva Investigational Site 12099, El Paso, Texas, United States

Teva Investigational Site 12071, Live Oak, Texas, United States

Teva Investigational Site 12054, San Antonio, Texas, United States

Teva Investigational Site 12145, Waco, Texas, United States

Teva Investigational Site 12046, Murray, Utah, United States

Teva Investigational Site 12041, South Burlington, Vermont, United States

Teva Investigational Site 12125, Richmond, Virginia, United States

Teva Investigational Site 12101, Seattle, Washington, United States

Teva Investigational Site 12109, Spokane, Washington, United States

Teva Investigational Site 12044, Tacoma, Washington, United States

Teva Investigational Site 12082, Greenfield, Wisconsin, United States

Additional Information

Starting date: June 2014
Last updated: August 11, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017